HTG2014-Section-Header-publications

Categories

Filter by Topics

1L therapy; bispecific antibodies 478P TA-ness ABC- type ADCC Gene Alteration adolescents AI alcohol consumption ALK alzheimer's Angiogenesis Anti-TNF Alpha Therapy antibody drug conjugates antiEGFR Apoptosis apoptosis Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells BCL2A1 BCL6 benign Biofluid Biology of neoplasia Biomarker biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation biomarkers Biomarkers Bladder Bladder cancer Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN blindness Blood Brain Breast Cancer Breast Milk Breast milk Burkitt lymphoma cancer genetics Cancer Genomics CAR-T-cells Cardiovascular Disease Castleman Disease CD10 CD3 CD8 CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid Cetuximab Chemokines Childhood Atopic Dermatitis children chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications cMET cognition Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity Dementia dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DLBCL COO DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Dysplasia ear Efficacy EGFR Muatations EMT Encephalophy end stage kidney disease Endothelial cell epidemiology epidermal growth factor receptor EGFRHER Epigenetics epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Extracellular Vesicles Evs extraction-free RNA workflow Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors FOLFOX7 Follicular lymphoma GEIS Gene Expression gene expression Gene expression analysis Gene Expression Profiling gene expression profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors HCC Head and neck cancer Head and Neck Cancer Heart hepatocellular carcinoma HER-2 HER2 HER2- Histone Deacetylase Inhibitors HLA-E Homing HPV HR+ HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours IMMUNOSARC immunotherapy Immunotherapy Inflammation Integrins inverted papilloma IRF4 ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Limb ischemia limbal stem cell deficiency LSCD Liposarcoma Liquid Biopsy Liver liver disease liver tissue Lung Lung cancer Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoid Neoplasia Lymphoma lymphoma lymphomas machine learning Machine Learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma Mesothelioma MET metastatic colorectal cancer CRC Method Comparison Microenvironment MicroRNA microRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mTOR pathway mTOR signaling multi-omics multiple myeloma Multiple Myeloma MUM1 Muscle mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic nivolumab NKG2A Non-alcoholic fatty liver disease non-Hodgkin Lymphoma Non-small cell lung cancer Novel Therapeutic Targets NTRK1 nuclease protection assay obesity OBP Oesophageal Adenocarcinoma Oncology Oncology-Biomarker OPSCC Optical imaging Oral cancer Oral Cancer Oral lesion Oral Squamous Cell Carcinoma Oropharyngeal Cancer Osteoarthritis Osteoclast Ovarian cancer PALLET PALOMA-2 Pan-Cancer PanB Pancreas Pancreatic Cancer Paralysis Parkinson's Disease Pathogenesis pathophysiology Pathway Analysis Pathway analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PENELOPE-B PFAS PFNA PFOS PIK3CA mutation PIP Placenta placenta Plasma Plasma miRNAs Platform Comparison PMAIP1 population based Precision medicine predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate Prostate Cancer prostate cancer prostate genomics Protein Protein Interaction network qNPA qPCR race disparities Radioimmunotherapy RAS Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety sarcoma Sarcoma SARS-CoV-2 Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures single cell Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium Squamous cell carcinoma squamous cell carcinoma STAT6 pathway Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid Synovial Sarcoma synthetic miRNA T-Cell T-cells targeted therapeutics Technology Comparison Testicular cancer Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer tislelizumab TMB tomentosin Toxicity TP53 mutation Transcriptome transcriptome profiling Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus VEGFR vestibular schwannoma VS virus Wound healing Xenograft Tissue Zanubrutinib

2020

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GerparNuevo

Karn, T., et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GerparNuevo. Annals of Oncology 2020 May 24; https://doi.org/10.1016/j.annonc.2020.05.015. In Press, Journal Pre-proof Online.

View External Link

Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era

Hwang, M., et al. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era.  Poster session presented at: United Sstates and Canadian Academy of Pathology (USCAP) 109th Annual Meeting 2020 FEB 29- MAR 5, Los Angeles, CA

Download pptx 4.4MB

2019

Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial

Sinn, B.V., et al. Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial. Abstract PD5-05 presented at: American Association for Cancer Research Breast Symposium; December 4-8, 2019. San Antonio, Texas.

View External Link

2018

Randomized phase II neoadjuvant study (GepartNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC)

Loibl, S., et al. Randomized phase II neoadjuvant study (GepartNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). Clinical Science Symposium Presented at: American Society of Clinical Oncology (ASCO); 2018 June 2, Chicago, IL.

Download pdf 2.8MB
View External Link

Targeted mRNA sequencing using small formalin-fixed, paraffin-embedded core biopsies to evaluate immune and tumor-associated gene expression in breast cancer

Sinn, B. V., et al Targeted mRNA sequencing using small formalin-fixed, paraffin embedded core biopsies to evaluate immune and tumor-associated gene expression in breast cancer. Abstract presented at: 102nd Annual Meeting of the German Society for Pathology 2018 May 24 – 16; Berlin, Germany, Abstract #AG13.03

Download pdf 112KB

Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).

Galsky, M. et al. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). Poster session presented at: Genitourniary Cancers Symposium; 2018 Feb 9; San Francisco, CA. J Clin Oncol 36, 2018 (suppl 6S; abstr 511).

View External Link

2017

Advanced molecular characterization of severe autoimmune toxicities associated with checkpoint inhibitor therapies

Balko J., et al. Advanced molecular characterization of severe autoimmune toxicities associated with checkpoint inhibitor therapies. Poster session presented at: The American Association for Cancer Research, 2017 Apr; Washington, DC

Download pdf 1.1MB

Heterogeneity in immune biomarker expression after acquisition of resistance to EGFR kirase inhibitors: Analysis of a case with small cell lung cancer transformation

Suda et. al. Heterogeneity in immune biomarker expression after acquisition of resistance to EGFR kirase inhibitors: Analysis of a case with small cell lung cancer transformation; J Thorac Oncol. 2017 Jun; 1216: 1015 

View External Link

Page last updated November 29, 2022